Charles A Rowland Jr
CIK 1383292 · VP, Chief Financial Officer · last filed 2026-02-09
Charles A Rowland Jr is a VP, Chief Financial Officer who has filed 84 SEC Form 4 insider transactions across 11 companies since 2008. The most recent filing, for GBIO, was dated Feb 9, 2026. Across all open-market trades the lifetime net is −$7.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $992.8K across reported positions. 3 SEC filings were submitted jointly with ENDO PHARMACEUTICALS HOLDINGS INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$992.8K
11
84
-$7.41M
Filer Profile
FURLONG, PA 18925
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Generation Bio Co. (GBIO) Delisted | Director | 0 | $5.34 | $0 | $2.03M | 13 | 2026-02-09 |
| VKTX | Director | 33,150 | $29.95 | $992.8K | -$3.13M | 7 | 2026-01-05 |
| Orchard Therapeutics plc (ORTX) Delisted | Director | 0 | $16.70 | $0 | $0 | 5 | 2024-01-24 |
| Nabriva Therapeutics plc (NBRV) Delisted | Director | 611 | $1.42 | $868 | $67.0K | 9 | 2022-08-03 |
| Blueprint Medicines Corp (BPMC) Delisted | Director | 5,812 | $129.46 | $752.4K | -$3.40M | 10 | 2021-06-04 |
| Viking Therapeutics, Inc. (VKTXW) Delisted | Director | 30,000 | $4.60 | $138.0K | $154.8K | 6 | 2021-01-06 |
| Vitae Pharmaceuticals, Inc (VTAE) Delisted | Director | — | — | — | $0 | 4 | 2016-10-25 |
| DNIB UNWIND, INC. (BIND) Delisted | Director | — | — | — | $0 | 2 | 2016-06-22 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Director | — | — | — | $0 | 2 | 2014-08-05 |
| VIROPHARMA INC (VPHM) Delisted | VP, Chief Financial Officer | 79,642 | — | — | -$3.13M | 19 | 2014-01-10 |
| ENDO HEALTH SOLUTIONS INC. (ENDP) Delisted | EVP, CFO & Treasurer | 6,699 | $0.29 | $2.0K | $0 | 2 | 2008-02-25 |
Recent Filings
84 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-09 | Generation Bio Co. (GBIO) Delisted | Mixed | −53,475 | $0 | EDGAR |
| 2026-01-05 | VKTX | Grant (A) | +3,150 | $0 | EDGAR |
| 2025-10-28 | VKTX | Mixed | — | -$1.83M | EDGAR |
| 2025-10-27 | VKTX | Notice (144) | −60,000 | -$2.13M | EDGAR |
| 2025-06-06 | Generation Bio Co. (GBIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-01-06 | VKTX | Grant (A) | — | $0 | EDGAR |
| 2024-06-10 | Generation Bio Co. (GBIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-01-24 | Orchard Therapeutics plc (ORTX) Delisted | Disp (D) | −12,294 | $0 | EDGAR |
| 2024-01-04 | VKTX | Grant (A) | — | $0 | EDGAR |
| 2023-12-05 | Generation Bio Co. (GBIO) Delisted | Buy (P) | +342,960 | $477.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.